New Delhi: The recent seizure of fake Mounjaro injections in Haryana has brought attention to a growing problem in India’s healthcare system, counterfeit high-demand medicines. The drug, developed by Eli Lilly, is widely known for treating type 2 diabetes and has also gained popularity for its weight-loss benefits.
During the raid, authorities recovered hundreds of fake injection pens along with packaging materials that closely resembled the original product. Initial investigations revealed that the counterfeit medicines were being assembled locally using low-cost raw materials and then sold through informal networks and online platforms. What made the situation more worrying is that these fake injections were being offered at lower prices, making them attractive to buyers who are already struggling with the high cost and limited availability of genuine medicines.
In India, the demand for modern weight-loss treatments has increased significantly in recent years. With rising cases of obesity and diabetes, especially in urban areas, more people are turning towards medical solutions. Social media trends and increasing awareness around fitness have also played a role in popularising such drugs. However, access remains a challenge. Genuine products are often expensive and not easily available everywhere, which creates space for counterfeit products to enter the market.
The Haryana case is believed to be part of a larger network. Authorities suspect that similar fake products may have been distributed in other cities as well, pointing towards a wider supply chain operating across states. This highlights the difficulty of controlling counterfeit medicines in a large and complex market like India, where distribution channels are spread out and not always strictly monitored.
Health experts are particularly concerned because injectable drugs like Mounjaro are not simple medicines. They require proper formulation, storage, and handling. If any of these factors are compromised, the drug may not work as intended or could even cause harm. In the case of counterfeit versions, there is no guarantee about the ingredients used or the conditions in which they were stored. This puts patients at serious risk, especially those who are already dealing with health conditions like diabetes.
Following the incident, Eli Lilly has supported the action taken by Indian authorities and stressed the importance of patient safety. The company has also advised people to purchase medicines only from authorised sellers and to avoid suspiciously low-priced offers. Regulators in India have started increasing checks and have alerted pharmacies to be cautious about unusual or unverified stock.
